https://www.biopharmawatch.com/news/CTOR/citius-oncology-lymphir-quality-of-life-data-eortc-cltg-2026 BiopharmaWatch en 2026-11-04T18:45:00.000Z Citius Oncology's Positive Quality of Life Data for LYMPHIR® (denileukin diftitox-cxdl) in Relapsed or Refractory Cutaneous T-Cell Lymphoma Presented at Premier Global CLTG Congress in Europe https://www.biopharmawatch.com/news/SNY/sanofi-ranked-first-2026-digital-innovation-index BiopharmaWatch en 2026-11-04T17:00:00.000Z CNS Summit Announces Sanofi as No. 1 in the 2026 Digital Innovation Index https://www.biopharmawatch.com/news/VALN/valneva-nine-month-2026-financial-results-report BiopharmaWatch en 2026-11-04T16:45:00.000Z Valneva to Report Nine-Month 2026 Consolidated Financial Results on November 24, 2026 https://www.biopharmawatch.com/news/MRNA/moderna-bundibugyo-ebola-vaccine-phase-2-3-study BiopharmaWatch en 2026-11-04T16:05:00.000Z Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study https://www.biopharmawatch.com/news/MBRX/moleculin-announces-annamycin-presentation-ash-2026 BiopharmaWatch en 2026-11-04T16:00:00.000Z Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting https://www.biopharmawatch.com/news/MRNA/moderna-mrna-2808-clinical-data-ash-2026 BiopharmaWatch en 2026-11-04T14:50:00.000Z Moderna Announces Oral Presentation of mRNA-2808 Clinical Data at 2026 American Society of Hematology Annual Meeting https://www.biopharmawatch.com/news/ONCY/pelareorep-hpv-immune-responses-anal-cancer BiopharmaWatch en 2026-11-04T14:30:00.000Z Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers https://www.biopharmawatch.com/news/BMY/bristol-myers-squibb-autumn-leaves-melanoma-awareness BiopharmaWatch en 2026-11-04T14:27:00.000Z Bristol Myers Squibb Canada Partners with TANK Worldwide and Ogilvy Health to Turn Autumn Leaves into a Guide for Spotting the Warning Signs of Melanoma https://www.biopharmawatch.com/news/COSM/cosmos-health-amazon-uk-sales-growth BiopharmaWatch en 2026-11-04T14:27:00.000Z Cosmos Health's Amazon UK Business Surpasses $2 Million in TTM Sales, Up 90%, with a 23% Net Profit Margin; Expects Sales to Grow Approximately 72% to $3.9 Million Over the Next Twelve Months https://www.biopharmawatch.com/news/MGX/metagenomi-therapeutics-mgx-001-ash-presentation BiopharmaWatch en 2026-11-04T14:25:00.000Z Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting https://www.biopharmawatch.com/news/XBIO/xenetic-biosciences-ash-presentation-dnase-i BiopharmaWatch en 2026-11-04T14:20:00.000Z Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-clinical-data-updates-ash-2026 BiopharmaWatch en 2026-11-04T14:15:00.000Z Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026 https://www.biopharmawatch.com/news/GILD/gilead-kite-ash-2026-presentations BiopharmaWatch en 2026-11-04T14:15:00.000Z Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026 https://www.biopharmawatch.com/news/HURA/tuhura-biosciences-ash-annual-meeting-presentations BiopharmaWatch en 2026-11-04T14:15:00.000Z TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition https://www.biopharmawatch.com/news/RIGL/rigel-phase-1b-data-r289-mds-ash-meeting BiopharmaWatch en 2026-11-04T14:15:00.000Z Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition https://www.biopharmawatch.com/news/IMMX/immix-biopharma-nxc-201-ash-2026-presentation BiopharmaWatch en 2026-11-04T14:15:00.000Z Immix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026 https://www.biopharmawatch.com/news/BNTX/penn-biontech-seed-fund-invests-emvena-therapeutics BiopharmaWatch en 2026-11-04T14:14:00.000Z Penn-BioNTech Innovative Therapeutics Seed Fund Announces First Investment https://www.biopharmawatch.com/news/CGEM/cullinan-therapeutics-ash-2026-presentations BiopharmaWatch en 2026-11-04T14:14:00.000Z Cullinan Therapeutics Announces Presentations for CLN-049, a FLT3 T Cell Engager, and Velinotamig, a BCMA T Cell Engager, at the 68th ASH Annual Meeting https://www.biopharmawatch.com/news/ONC/fda-priority-review-brukinsa-mcl BiopharmaWatch en 2026-11-04T14:13:00.000Z U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma https://www.biopharmawatch.com/news/A/agilent-completes-acquisition-of-proscia BiopharmaWatch en 2026-11-04T14:12:00.000Z Agilent Completes Acquisition of Proscia https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-ash-2026-iomab-act-results BiopharmaWatch en 2026-11-04T14:11:00.000Z Actinium Pharmaceuticals Announces Three ASH 2026 Abstracts Highlighting Iomab-ACT Clinical Results in CAR T-Cell Therapy and Sickle Cell Disease https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-ash-2026-actimab-a-results BiopharmaWatch en 2026-11-04T14:05:00.000Z Actinium Pharmaceuticals Announces ASH 2026 Abstract Highlighting Long-Term Results of Actimab-A in Combination with CLAG-M in Relapsed or Refractory AML https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-ash-meeting-2026 BiopharmaWatch en 2026-11-04T14:05:00.000Z Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition https://www.biopharmawatch.com/news/DARE/dare-bioscience-presentation-stifel-2026-conference BiopharmaWatch en 2026-11-04T14:05:00.000Z Daré Bioscience to Present at Stifel’s 2026 Healthcare Conference https://www.biopharmawatch.com/news/IRON/disc-medicine-ash-annual-meeting-2026 BiopharmaWatch en 2026-11-04T14:05:00.000Z Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting https://www.biopharmawatch.com/news/LEXX/lexaria-new-pharmaceutical-agreement-dehydratech BiopharmaWatch en 2026-11-04T14:04:24.000Z Lexaria Enters a New Pharmaceutical Agreement for DehydraTECH https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-80-million-private-placement BiopharmaWatch en 2026-11-04T14:02:00.000Z Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission https://www.biopharmawatch.com/news/KURA/kura-kyowa-ziftomenib-data-ash-2026 BiopharmaWatch en 2026-11-04T14:02:00.000Z Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026 https://www.biopharmawatch.com/news/IMNM/immunome-first-in-human-data-im-1021-ash-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026 https://www.biopharmawatch.com/news/KPTI/karyopharm-selinexor-data-ash-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH) https://www.biopharmawatch.com/news/CRVS/corvus-soquelitinib-alps-trial-data-ash-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Corvus Pharmaceuticals Announces Initial Data from Soquelitinib Clinical Trial in Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) will be Presented at the 68ᵗʰ American Society for Hematology Annual Meeting & Exposition https://www.biopharmawatch.com/news/SNDX/syndax-host-ash-investor-event-december-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Syndax to Host ASH Investor Event in Person and via Webcast on December 14, 2026 https://www.biopharmawatch.com/news/LYEL/lyell-immunopharma-ronde-cel-data-ash-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma https://www.biopharmawatch.com/news/AGIO/agios-new-clinical-data-ash-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Agios to Highlight Strength and Differentiation of Rare Hematology Portfolio with New Clinical Data for Mitapivat in Sickle Cell Disease and AG-236 in Polycythemia Vera at ASH 2026 https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-zugo-cel-ash-meeting-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition https://www.biopharmawatch.com/news/LKFT/lakefront-biotherapeutics-poster-presentation-ash-2026 BiopharmaWatch en 2026-11-04T14:01:00.000Z Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-beacon-trial-ash-presentation BiopharmaWatch en 2026-11-04T14:00:42.000Z Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting https://www.biopharmawatch.com/news/CRBU/caribou-biosciences-ash-2026-presentations BiopharmaWatch en 2026-11-04T14:00:39.000Z Caribou Biosciences Announces Presentations at the 2026 American Society of Hematology (ASH) Annual Meeting https://www.biopharmawatch.com/news/AMLX/amylyx-investor-event-obesityweek-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts https://www.biopharmawatch.com/news/EVAX/evaxion-evx-04-ash-2026-presentation BiopharmaWatch en 2026-11-04T14:00:00.000Z Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting https://www.biopharmawatch.com/news/SLN/silence-therapeutics-divesiran-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Silence Therapeutics Announces Oral Presentation on SANRECO Phase 2 Study of Divesiran in Polycythemia Vera at ASH 2026 https://www.biopharmawatch.com/news/INCY/incyte-new-data-hematology-portfolio-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026 https://www.biopharmawatch.com/news/BMRN/biomarin-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-04T14:00:00.000Z BioMarin to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ADCT/adct-zynlonta-ash-annual-meeting-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z ADC Therapeutics Announces Abstracts at the 68th ASH Annual Meeting Highlighting Breadth of ZYNLONTA® Clinical Program https://www.biopharmawatch.com/news/GERN/geron-rytelos-data-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Geron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026 https://www.biopharmawatch.com/news/SLS/sellas-life-sciences-positive-phase-2-data-sls009 BiopharmaWatch en 2026-11-04T14:00:00.000Z SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026 https://www.biopharmawatch.com/news/SNDX/syndax-ash-2026-abstracts-revumenib-axatilimab BiopharmaWatch en 2026-11-04T14:00:00.000Z Syndax Highlights Acceptance of 19 Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Abstracts, Including 7 for Oral Presentation, at ASH 2026 https://www.biopharmawatch.com/news/CLRB/cellectar-biosciences-ash-presentation-iopofosine BiopharmaWatch en 2026-11-04T14:00:00.000Z Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition https://www.biopharmawatch.com/news/DMRA/damora-therapeutics-dmr-001-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting https://www.biopharmawatch.com/news/LEGN/legend-biotech-carvykti-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026 https://www.biopharmawatch.com/news/CLYM/climb-bio-budoprutug-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition https://www.biopharmawatch.com/news/GMAB/genmab-epcoritamab-ash-2026 BiopharmaWatch en 2026-11-04T14:00:00.000Z Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-canaccord-genuity-forum-participation BiopharmaWatch en 2026-11-04T13:55:00.000Z Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum https://www.biopharmawatch.com/news/ONMD/onemednet-mid-six-figure-reorder-radiology-models BiopharmaWatch en 2026-11-04T13:45:00.000Z OneMedNet Receives Mid Six-Figure Re-Order from Foundation Model Company Developing Radiology Models https://www.biopharmawatch.com/news/ICU/seastar-medical-q3-results-november-2026 BiopharmaWatch en 2026-11-04T13:41:00.000Z SeaStar Medical to Report Third Quarter Financial Results on November 11, 2026 https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-ovarian-cancer-car-t-trial-esmo-2026 BiopharmaWatch en 2026-11-04T13:35:00.000Z Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026 https://www.biopharmawatch.com/news/LH/labcorp-acquisition-millennium-health BiopharmaWatch en 2026-11-04T13:30:00.000Z Labcorp Completes Acquisition of Millennium Health https://www.biopharmawatch.com/news/TLPH/talphera-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-04T13:30:00.000Z Talphera to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026 https://www.biopharmawatch.com/news/ERAS/tango-erasca-phase-1-2-study-vopimetostat-eras-0015 BiopharmaWatch en 2026-11-04T13:30:00.000Z Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 https://www.biopharmawatch.com/news/APRE/aprea-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T13:30:00.000Z Aprea Therapeutics Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MDCX/medicus-pharma-skinject-business-combination BiopharmaWatch en 2026-11-04T13:30:00.000Z Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing https://www.biopharmawatch.com/news/INBS/intelligent-bio-solutions-webull-biotech-webinar BiopharmaWatch en 2026-11-04T13:30:00.000Z Intelligent Bio Solutions to Present at the Webull Biotech Webinar on November 12 https://www.biopharmawatch.com/news/CLNN/clene-reports-q3-2026-results-and-highlights BiopharmaWatch en 2026-11-04T13:30:00.000Z Clene Reports Third Quarter 2026 Financial Results and Recent Operating Highlights https://www.biopharmawatch.com/news/BCAX/bicara-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261104 BiopharmaWatch en 2026-11-04T13:30:00.000Z Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/HYFT/mindwalk-teva-australia-antibody-discovery-agreement BiopharmaWatch en 2026-11-04T13:01:00.000Z MindWalk Announces Agreement with Teva Australia to Support Defined Antibody-Discovery Workflows https://www.biopharmawatch.com/news/PMVP/rezatapopt-pynnacle-data-ena-2026 BiopharmaWatch en 2026-11-04T13:00:37.000Z Pivotal Phase 2 Rezatapopt PYNNACLE Data to Be Featured in Late-Breaking Oral Presentation at ENA 2026 https://www.biopharmawatch.com/news/ALNY/alnylam-webcast-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-04T13:00:00.000Z Alnylam to Webcast Presentation at the Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/UNH/unitedhealth-group-board-authorizes-payment-quarterly-dividend BiopharmaWatch en 2026-11-04T13:00:00.000Z UnitedHealth Group Board Authorizes Payment of Quarterly Dividend https://www.biopharmawatch.com/news/INCY/incyte-present-upcoming-investor-conferences BiopharmaWatch en 2026-11-04T13:00:00.000Z Incyte to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/IBRX/immunitybio-first-patients-europe-anktiva-bcg BiopharmaWatch en 2026-11-04T13:00:00.000Z ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ https://www.biopharmawatch.com/news/ENVB/enveric-biosciences-eb-003-qeeg-study-results BiopharmaWatch en 2026-11-04T13:00:00.000Z Enveric Biosciences Reports Differentiated Brain Activity Profile for EB-003 in Preclinical qEEG Study https://www.biopharmawatch.com/news/LH/labcorp-speak-ubs-global-healthcare-conference BiopharmaWatch en 2026-11-04T13:00:00.000Z Labcorp to Speak at the UBS Global Healthcare Conference https://www.biopharmawatch.com/news/MDT/medtronic-michael-j-fox-foundation-parkinson-dbs-education BiopharmaWatch en 2026-11-04T13:00:00.000Z Medtronic and Michael J. Fox Foundation Partner to Help More People with Parkinson's Understand Deep Brain Stimulation https://www.biopharmawatch.com/news/ETRA/electra-therapeutics-presentation-jefferies-conference-2026 BiopharmaWatch en 2026-11-04T13:00:00.000Z Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/ELTX/elicio-therapeutics-kol-event-november-2026 BiopharmaWatch en 2026-11-04T13:00:00.000Z Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC https://www.biopharmawatch.com/news/NTLA/intellia-completes-enrollment-magnitude-2-trial-nex-z BiopharmaWatch en 2026-11-04T13:00:00.000Z Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN) https://www.biopharmawatch.com/news/CLGN/collplant-name-change-optiphi-computing BiopharmaWatch en 2026-11-04T13:00:00.000Z CollPlant Announces Proposed Name Change to OptiPhi Computing Reflecting Expansion to Computing with Light https://www.biopharmawatch.com/news/SCTX/scribe-therapeutics-presents-data-aha-scientific-sessions-2026 BiopharmaWatch en 2026-11-04T13:00:00.000Z Scribe Therapeutics to Present Updated Data on PCSK9-Targeting Epigenetic Silencing and LPA-Targeting Gene Editing Programs at American Heart Association (AHA) Scientific Sessions 2026 https://www.biopharmawatch.com/news/ACTU/actuate-therapeutics-elraglusib-preclinical-data-ena-2026 BiopharmaWatch en 2026-11-04T13:00:00.000Z Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026 https://www.biopharmawatch.com/news/URGN/urogen-reports-zusduri-revenue-q3-2026 BiopharmaWatch en 2026-11-04T13:00:00.000Z UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights https://www.biopharmawatch.com/news/BIVI/biovie-announces-4-74-million-offering BiopharmaWatch en 2026-11-04T13:00:00.000Z BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules https://www.biopharmawatch.com/news/JSPR/jasper-therapeutics-reverse-stock-split BiopharmaWatch en 2026-11-04T13:00:00.000Z Jasper Therapeutics Announces 1-for-30 Reverse Stock Split https://www.biopharmawatch.com/news/SEPN/septerna-selects-sep-204-for-graves-disease-and-ted BiopharmaWatch en 2026-11-04T13:00:00.000Z Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting https://www.biopharmawatch.com/news/STRO/sutro-biopharma-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-04T13:00:00.000Z Sutro Biopharma to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PCSA/processa-pharmaceuticals-leadership-appointments BiopharmaWatch en 2026-11-04T13:00:00.000Z Processa Pharmaceuticals Announces Key Leadership Appointments https://www.biopharmawatch.com/news/PHAT/phathom-pharmaceuticals-november-investor-conferences BiopharmaWatch en 2026-11-04T13:00:00.000Z Phathom Pharmaceuticals to Participate in November Investor Conferences https://www.biopharmawatch.com/news/NCEL/newcelx-divests-mazindol-portfolio-to-rea-holdings BiopharmaWatch en 2026-11-04T13:00:00.000Z NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments https://www.biopharmawatch.com/news/RYTM/nice-guidance-imcivree-bardet-biedl-syndrome BiopharmaWatch en 2026-11-04T13:00:00.000Z Rhythm Pharmaceuticals Announces NICE Guidance for IMCIVREE® (Setmelanotide) Updated to Include Adults Living with Bardet-Biedl Syndrome https://www.biopharmawatch.com/news/STIM/neuronetics-q3-2026-financial-results BiopharmaWatch en 2026-11-04T12:50:00.000Z Neuronetics Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-refinances-credit-facility BiopharmaWatch en 2026-11-04T12:30:00.000Z Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity https://www.biopharmawatch.com/news/DRIO/dariohealth-appoints-john-palumbo-chairman-board BiopharmaWatch en 2026-11-04T12:30:00.000Z Dario Names Veteran Healthcare Executive John R. Palumbo Chairman of the Board as Company Positions Itself to Lead the Convergence of Consumer and Payer-Funded Care https://www.biopharmawatch.com/news/IMRX/immuneering-atebimetinib-potential-combinations-cancers BiopharmaWatch en 2026-11-04T12:30:00.000Z Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium https://www.biopharmawatch.com/news/MDLN/medline-reports-third-quarter-nine-months-2026-results BiopharmaWatch en 2026-11-04T12:30:00.000Z Medline Reports Third Quarter and Nine Months 2026 Results https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-corporate-update-q3-results BiopharmaWatch en 2026-11-04T12:30:00.000Z NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results https://www.biopharmawatch.com/news/CNSY/cerenome-aetna-cnside-agreement BiopharmaWatch en 2026-11-04T12:30:00.000Z Cerenome Secures National In-Network Agreement with Aetna for CNSide® https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-jefferies-conference-2026 BiopharmaWatch en 2026-11-04T12:30:00.000Z Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/HBIO/harvard-bioscience-canaccord-genuity-forum-2026 BiopharmaWatch en 2026-11-04T12:30:00.000Z Harvard Bioscience to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-q3-2026-results-bp-205-data BiopharmaWatch en 2026-11-04T12:30:00.000Z Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile https://www.biopharmawatch.com/news/UNCY/unicycive-therapeutics-guggenheim-conference-2026 BiopharmaWatch en 2026-11-04T12:05:00.000Z Unicycive Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-q3-2026-financial-results BiopharmaWatch en 2026-11-04T12:05:00.000Z Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update https://www.biopharmawatch.com/news/QURE/uniqure-q3-2026-financial-results-update BiopharmaWatch en 2026-11-04T12:05:00.000Z uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update https://www.biopharmawatch.com/news/RPRX/royalty-pharma-q3-2026-results BiopharmaWatch en 2026-11-04T12:03:28.000Z Royalty Pharma reports third quarter 2026 results https://www.biopharmawatch.com/news/GERN/geron-corporation-q3-2026-financial-results BiopharmaWatch en 2026-11-04T12:03:00.000Z Geron Corporation Reports Third Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/VRDN/viridian-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T12:01:00.000Z Viridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress https://www.biopharmawatch.com/news/CRL/charles-river-laboratories-q3-2026-results BiopharmaWatch en 2026-11-04T12:00:00.000Z Charles River Laboratories Announces Third-Quarter 2026 Results https://www.biopharmawatch.com/news/ENTA/enanta-pharmaceuticals-investor-conferences-2026 BiopharmaWatch en 2026-11-04T12:00:00.000Z Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PODD/insulet-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-04T12:00:00.000Z Insulet Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/NTRA/signatera-head-neck-cancer-publications BiopharmaWatch en 2026-11-04T12:00:00.000Z Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability https://www.biopharmawatch.com/news/MASS/908-devices-stifel-2026-healthcare-conference BiopharmaWatch en 2026-11-04T12:00:00.000Z 908 Devices to Participate in the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/ANTX/an2-therapeutics-nominates-an2-504661-hpp BiopharmaWatch en 2026-11-04T12:00:00.000Z AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP) https://www.biopharmawatch.com/news/BRKR/bruker-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-04T12:00:00.000Z Bruker Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/UTHR/united-therapeutics-buys-down-ralinepag-royalty BiopharmaWatch en 2026-11-04T12:00:00.000Z United Therapeutics Announces Buydown of Ralinepag Royalty https://www.biopharmawatch.com/news/INSM/insmed-investor-conferences-november-december-2026 BiopharmaWatch en 2026-11-04T12:00:00.000Z Insmed to Present at November and December 2026 Investor Conferences https://www.biopharmawatch.com/news/GNPX/genprex-trop2-predictive-biomarker-lung-cancer BiopharmaWatch en 2026-11-04T12:00:00.000Z Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-bh-30236-ash-presentation BiopharmaWatch en 2026-11-04T12:00:00.000Z BlossomHill Therapeutics Announces Upcoming Presentation for BH-30236, an Oral Macrocyclic CLK Inhibitor, at the 68th American Society of Hematology (ASH) Annual Meeting https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-04T12:00:00.000Z Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-ser-155-ir-ec-development BiopharmaWatch en 2026-11-04T12:00:00.000Z Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) https://www.biopharmawatch.com/news/OCGN/ocugen-provides-business-update-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-04T12:00:00.000Z Ocugen Provides Business Update with Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ODTX/odyssey-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-04T12:00:00.000Z Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/BCRX/biocryst-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-04T12:00:00.000Z BioCryst Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-q3-2026-results-highlights BiopharmaWatch en 2026-11-04T12:00:00.000Z Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-jefferies-conference-2026 BiopharmaWatch en 2026-11-04T12:00:00.000Z Relmada Therapeutics to Participate at the Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/OPCH/option-care-health-q3-2026-financial-results BiopharmaWatch en 2026-11-04T12:00:00.000Z Option Care Health Announces Financial Results for the Third Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/RGEN/repligen-corporation-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-04T12:00:00.000Z Repligen Corporation to Present at Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/RADX/radiopharm-theranostics-fda-alignment-rad101-trial BiopharmaWatch en 2026-11-04T12:00:00.000Z Radiopharm Theranostics Announces Alignment with U.S. FDA on Single Pivotal Phase 3 Trial for RAD101 in Diagnosis of Brain Metastases https://www.biopharmawatch.com/news/ACIU/ac-immune-q3-2026-financial-update BiopharmaWatch en 2026-11-04T12:00:00.000Z AC Immune Third Quarter 2026 Financial and Corporate Update https://www.biopharmawatch.com/news/MLTX/moonlake-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-04T12:00:00.000Z MoonLake Reports Third Quarter 2026 Financial Results and Provides a Business Update https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-guggenheim-healthcare-conference BiopharmaWatch en 2026-11-04T12:00:00.000Z Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-guggenheim-conference-2026 BiopharmaWatch en 2026-11-04T12:00:00.000Z Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-dt120-phase-3-data-nei-fall-congress BiopharmaWatch en 2026-11-04T12:00:00.000Z Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress https://www.biopharmawatch.com/news/VTRS/viatris-announces-quarterly-dividend-20261104 BiopharmaWatch en 2026-11-04T11:59:00.000Z Viatris Announces Quarterly Dividend https://www.biopharmawatch.com/news/QTTB/q32-bio-reports-q3-2026-results-corporate-update BiopharmaWatch en 2026-11-04T11:59:00.000Z Q32 Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-employee-inducement-grants BiopharmaWatch en 2026-11-04T11:57:00.000Z Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 https://www.biopharmawatch.com/news/BDX/bd-names-bridget-bagnato-president-peripheral-intervention BiopharmaWatch en 2026-11-04T11:50:00.000Z BD Names Bridget Bagnato Worldwide President of Peripheral Intervention https://www.biopharmawatch.com/news/COR/cencora-fiscal-2026-fourth-quarter-results BiopharmaWatch en 2026-11-04T11:35:00.000Z Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results https://www.biopharmawatch.com/news/COR/cencora-new-organizational-structure BiopharmaWatch en 2026-11-04T11:35:00.000Z Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus https://www.biopharmawatch.com/news/CVS/cvs-health-separation-into-two-companies BiopharmaWatch en 2026-11-04T11:31:00.000Z CVS Health Announces Intent to Create Two Distinct Leaders in Healthcare https://www.biopharmawatch.com/news/UTHR/united-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-04T11:30:00.000Z United Therapeutics Corporation Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CMPS/compass-pathways-stifel-2026-healthcare-conference BiopharmaWatch en 2026-11-04T11:30:00.000Z Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th https://www.biopharmawatch.com/news/PRGO/perrigo-third-quarter-2026-results BiopharmaWatch en 2026-11-04T11:30:00.000Z Perrigo Reports Third Quarter 2026 Financial Results From Continuing Operations https://www.biopharmawatch.com/news/CVS/cvs-health-reports-q3-2026-results BiopharmaWatch en 2026-11-04T11:30:00.000Z CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-third-quarter-2026-results BiopharmaWatch en 2026-11-04T11:30:00.000Z Zimmer Biomet Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/blog/big-pharma-q3-2026-earnings-ranked BiopharmaWatch en 2026-11-04T11:00:06.527Z Big Pharma Q3 2026 Earnings Ranked: Lilly Takes the Growth https://www.biopharmawatch.com/news/LIVN/livanova-reports-q3-2026-results-guidance-raise BiopharmaWatch en 2026-11-04T11:00:00.000Z LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-november-2026-investor-events BiopharmaWatch en 2026-11-04T11:00:00.000Z IDEAYA Biosciences to Participate in Upcoming November 2026 Investor Relations Events https://www.biopharmawatch.com/news/WST/west-participate-upcoming-investor-conference BiopharmaWatch en 2026-11-04T11:00:00.000Z West to Participate in Upcoming Investor Conference https://www.biopharmawatch.com/news/BDSX/biodesix-participate-upcoming-investor-conferences-20261104 BiopharmaWatch en 2026-11-04T11:00:00.000Z Biodesix to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ABBV/nxera-pharma-abbvie-license-agreement-nxe0033744 BiopharmaWatch en 2026-11-04T08:41:00.000Z Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease https://www.biopharmawatch.com/blog/phase-2-3-readouts-week-of-2026-11-02 BiopharmaWatch en 2026-11-04T07:15:26.320Z Vonaprument Phase 3 Readout in Geographic Atrophy: Phase 2 and 3 Readouts Nov 2, 2026 https://www.biopharmawatch.com/news/NVO/novo-raises-outlook-glp1-momentum-q3-results BiopharmaWatch en 2026-11-04T06:30:00.000Z Novo raises full-year outlook on continued GLP-1 momentum, with third-quarter adjusted operating profit increasing 27% at CER to DKK 31,720 million https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261104 BiopharmaWatch en 2026-11-04T01:45:00.000Z Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/TECH/bio-techne-declares-dividend-november-2026 BiopharmaWatch en 2026-11-04T01:30:00.000Z BIO-TECHNE DECLARES DIVIDEND https://www.biopharmawatch.com/news/PNTG/pennant-third-quarter-2026-earnings-release BiopharmaWatch en 2026-11-03T23:30:00.000Z Pennant Announces Third Quarter 2026 Earnings Release and Call https://www.biopharmawatch.com/news/MMM/3m-settlement-pfas-personal-injury-claims BiopharmaWatch en 2026-11-03T23:00:00.000Z 3M Reaches Broad Resolution of AFFF Personal Injury Litigation https://www.biopharmawatch.com/news/CRDL/cardiol-therapeutics-at-the-market-offering BiopharmaWatch en 2026-11-03T22:03:00.000Z Cardiol Therapeutics Announces At-The-Market Equity Offering Program With Jefferies LLC https://www.biopharmawatch.com/news/MMM/3m-board-approves-6-billion-share-repurchase BiopharmaWatch en 2026-11-03T21:59:00.000Z 3M Board Approves New $6 Billion Share Repurchase Authorization, Declares Quarterly Dividend https://www.biopharmawatch.com/news/UFPT/ufp-technologies-announces-strong-q3-results BiopharmaWatch en 2026-11-03T21:54:00.000Z UFP Technologies Announces Strong Q3 Results https://www.biopharmawatch.com/news/AUTL/autolus-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261103 BiopharmaWatch en 2026-11-03T21:45:00.000Z Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MDWD/mediwound-15-million-bought-deal-offering BiopharmaWatch en 2026-11-03T21:40:00.000Z MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares https://www.biopharmawatch.com/news/XFOR/x4-pharmaceuticals-conferences-november-2026 BiopharmaWatch en 2026-11-03T21:30:30.000Z X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026 https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-participate-upcoming-investor-conferences-20261103 BiopharmaWatch en 2026-11-03T21:30:00.000Z Travere Therapeutics to Participate at Upcoming Investor Conferences https://www.biopharmawatch.com/news/GH/kevin-sayer-joins-guardant-health-board BiopharmaWatch en 2026-11-03T21:30:00.000Z Kevin Sayer Joins Guardant Health Board of Directors https://www.biopharmawatch.com/news/VKTX/viking-therapeutics-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-03T21:30:00.000Z Viking Therapeutics to Participate at Upcoming Investor Conferences https://www.biopharmawatch.com/news/VNDA/vanda-pharmaceuticals-november-2026-investor-conferences BiopharmaWatch en 2026-11-03T21:30:00.000Z Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences https://www.biopharmawatch.com/news/XLO/xilio-therapeutics-stifel-2026-healthcare-conference BiopharmaWatch en 2026-11-03T21:30:00.000Z Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/OLMA/olema-oncology-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261103 BiopharmaWatch en 2026-11-03T21:30:00.000Z Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/PACS/pacs-group-third-quarter-2026-results BiopharmaWatch en 2026-11-03T21:15:00.000Z PACS Group, Inc. Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-participate-upcoming-investor-conferences-20261103 BiopharmaWatch en 2026-11-03T21:15:00.000Z Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-participate-upcoming-investor-conferences-20261103 BiopharmaWatch en 2026-11-03T21:15:00.000Z Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-q3-2026-update BiopharmaWatch en 2026-11-03T21:15:00.000Z First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CBIO/crescent-biopharma-announces-grants-inducement-awards-20261103 BiopharmaWatch en 2026-11-03T21:15:00.000Z Crescent Biopharma Announces Grants of Inducement Awards https://www.biopharmawatch.com/news/TRAX/first-tracks-biotherapeutics-announces-participation-upcoming-investor-conferences BiopharmaWatch en 2026-11-03T21:15:00.000Z First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/HQY/healthequity-third-quarter-earnings-release BiopharmaWatch en 2026-11-03T21:11:00.000Z HealthEquity Schedules Third Quarter Earnings Release Date https://www.biopharmawatch.com/news/PAHC/phibro-animal-health-corporation-declares-quarterly-dividend-20261103 BiopharmaWatch en 2026-11-03T21:10:00.000Z Phibro Animal Health Corporation Declares Quarterly Dividend https://www.biopharmawatch.com/news/SRTA/strata-critical-medical-ubs-conference-2026 BiopharmaWatch en 2026-11-03T21:05:00.000Z Strata Critical Medical to Present at the UBS Global Healthcare Conference https://www.biopharmawatch.com/news/USNA/usana-health-sciences-third-quarter-2026-results BiopharmaWatch en 2026-11-03T21:05:00.000Z USANA Health Sciences Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/TWST/twist-bioscience-proposed-settlement BiopharmaWatch en 2026-11-03T21:05:00.000Z Notice of Proposed Derivative Settlement: Twist Bioscience Corporation https://www.biopharmawatch.com/news/ADUS/addus-homecare-q3-2026-results BiopharmaWatch en 2026-11-03T21:05:00.000Z Addus HomeCare Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CTNM/contineum-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-03T21:05:00.000Z Contineum Therapeutics Reports Third-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CORT/corcept-therapeutics-q3-financial-results-update BiopharmaWatch en 2026-11-03T21:05:00.000Z Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/MYO/myomo-attend-craig-hallum-alpha-select-conference BiopharmaWatch en 2026-11-03T21:05:00.000Z Myomo to Attend the 17th Annual Craig Hallum Alpha Select Conference https://www.biopharmawatch.com/news/HYPR/hyperfine-participate-jefferies-btig-conferences BiopharmaWatch en 2026-11-03T21:05:00.000Z Hyperfine to Participate in Jefferies London and BTIG Tech-Enabled Healthcare Conferences https://www.biopharmawatch.com/news/EXEL/exelixis-webcast-fireside-chats-investor-conferences-november BiopharmaWatch en 2026-11-03T21:05:00.000Z Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November https://www.biopharmawatch.com/news/QDEL/quidelortho-q3-2026-financial-results BiopharmaWatch en 2026-11-03T21:05:00.000Z QuidelOrtho Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CPIX/cumberland-pharmaceuticals-q3-2026-update BiopharmaWatch en 2026-11-03T21:05:00.000Z CUMBERLAND PHARMACEUTICALS TO ANNOUNCE COMPANY UPDATE & Q3 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-neuropsychiatry-pipeline-nei-fall-congress BiopharmaWatch en 2026-11-03T21:05:00.000Z Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress https://www.biopharmawatch.com/news/MGNX/macrogenics-appoints-kuriakose-vasconcelles-board BiopharmaWatch en 2026-11-03T21:05:00.000Z MacroGenics Announces Appointments of Emil Kuriakose, M.D., and Michael Vasconcelles, M.D., to Board of Directors https://www.biopharmawatch.com/news/MOBI/mobia-medical-wolfe-research-conference-2026 BiopharmaWatch en 2026-11-03T21:05:00.000Z Mobia Medical to Participate in the 8th Annual Wolfe Research Healthcare Conference https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-stifel-2026-conference BiopharmaWatch en 2026-11-03T21:05:00.000Z Inspire Medical Systems, Inc. to Present at the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/MLYS/mineralys-therapeutics-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-03T21:05:00.000Z Mineralys Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/LTGO/latigo-biotherapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-11-03T21:05:00.000Z Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November https://www.biopharmawatch.com/news/FATE/fate-therapeutics-inducement-awards-nasdaq-rule BiopharmaWatch en 2026-11-03T21:05:00.000Z Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/TMCI/treace-presents-stifel-2026-healthcare-conference BiopharmaWatch en 2026-11-03T21:05:00.000Z Treace to Present at the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/CBLL/ceribell-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-03T21:05:00.000Z Ceribell Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-q3-2026-results-revenue-guidance BiopharmaWatch en 2026-11-03T21:05:00.000Z Alamar Biosciences Reports Third Quarter 2026 Financial Results and Raises 2026 Revenue Guidance https://www.biopharmawatch.com/news/TARS/tarsus-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-03T21:05:00.000Z Tarsus Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/INNV/innovage-financial-results-fiscal-q1-2027 BiopharmaWatch en 2026-11-03T21:05:00.000Z InnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2026 https://www.biopharmawatch.com/news/ZVRA/zevra-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-03T21:05:00.000Z Zevra Reports Third Quarter 2026 Financial Results and Corporate Update https://www.biopharmawatch.com/news/RXST/rxsight-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-03T21:05:00.000Z RxSight, Inc. Reports Third Quarter 2026 Results https://www.biopharmawatch.com/news/IRIX/iridex-third-quarter-2026-financial-results BiopharmaWatch en 2026-11-03T21:05:00.000Z Iridex to Report Third Quarter 2026 Financial Results on November 17, 2026 https://www.biopharmawatch.com/news/TDOC/teladoc-health-inducement-awards-nyse-rule-303a08 BiopharmaWatch en 2026-11-03T21:05:00.000Z Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08 https://www.biopharmawatch.com/news/OCS/oculis-q3-2026-financial-results-pipeline-catalysts BiopharmaWatch en 2026-11-03T21:05:00.000Z Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-gsk-proteomic-study-precision-medicine BiopharmaWatch en 2026-11-03T21:03:00.000Z Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine https://www.biopharmawatch.com/news/GMED/globus-medical-acquires-synaptive-medical BiopharmaWatch en 2026-11-03T21:02:00.000Z Globus Medical Acquires Synaptive Medical, Strengthening Its Position in Cranial Neurosurgery https://www.biopharmawatch.com/news/AURA/aura-biosciences-investor-conference-2026 BiopharmaWatch en 2026-11-03T21:02:00.000Z Aura Biosciences to Participate in Upcoming Investor Conference https://www.biopharmawatch.com/news/MIRM/mirum-pharmaceuticals-q3-2026-results-update BiopharmaWatch en 2026-11-03T21:01:00.000Z Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/ATRC/atricure-reports-third-quarter-2026-results BiopharmaWatch en 2026-11-03T21:01:00.000Z AtriCure Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AMGN/amgen-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-03T21:01:00.000Z AMGEN REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS https://www.biopharmawatch.com/news/AQST/aquestive-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-03T21:01:00.000Z Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/RARE/ultragenyx-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-03T21:01:00.000Z Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027 https://www.biopharmawatch.com/news/DNLI/denali-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-03T21:01:00.000Z Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/ARDX/ardelyx-q3-2026-financial-results-update BiopharmaWatch en 2026-11-03T21:01:00.000Z Ardelyx Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/XENE/xenon-present-upcoming-investor-conferences-20261103 BiopharmaWatch en 2026-11-03T21:01:00.000Z Xenon to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/NRIX/nurix-therapeutics-sanofi-sar448272-discontinued BiopharmaWatch en 2026-11-03T21:01:00.000Z Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272 https://www.biopharmawatch.com/news/GLUE/monte-rosa-therapeutics-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-11-03T21:01:00.000Z Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-q3-2026-financial-results-update BiopharmaWatch en 2026-11-03T21:01:00.000Z Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/ORIC/oric-pharmaceuticals-investor-conferences-november-2026 BiopharmaWatch en 2026-11-03T21:01:00.000Z ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ARWR/arrowhead-webcast-2026-fiscal-results BiopharmaWatch en 2026-11-03T21:00:00.000Z Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results https://www.biopharmawatch.com/news/ALKS/alkermes-investor-conferences-november-2026 BiopharmaWatch en 2026-11-03T21:00:00.000Z Alkermes to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/CYTK/cytokinetics-participate-november-investor-conferences BiopharmaWatch en 2026-11-03T21:00:00.000Z Cytokinetics to Participate in November Investor Conferences https://www.biopharmawatch.com/news/MDT/medtronic-symplicity-blood-pressure-study-results BiopharmaWatch en 2026-11-03T19:34:00.000Z TCT26: Medtronic Symplicity blood pressure procedure shows significant blood pressure drops in SPYRAL AFFIRM real-world study https://www.biopharmawatch.com/news/KAPA/kairos-pharma-presents-cancer-research-conference BiopharmaWatch en 2026-11-03T16:45:00.000Z Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development https://www.biopharmawatch.com/news/RFL/rafael-holdings-guggenheim-healthcare-conference-2026 BiopharmaWatch en 2026-11-03T16:14:00.000Z Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/CYH/community-health-systems-ubs-conference-2026 BiopharmaWatch en 2026-11-03T16:00:00.000Z Community Health Systems Announces Participation in the 2026 UBS Global Healthcare Conference https://www.biopharmawatch.com/news/UTMD/utah-medical-products-increases-dividend BiopharmaWatch en 2026-11-03T15:00:00.000Z Utah Medical Products, Inc. Increases Quarterly Dividend https://www.biopharmawatch.com/news/NVO/novo-nordisk-s-share-repurchase-programme-20261103 BiopharmaWatch en 2026-11-03T14:51:00.000Z Novo Nordisk A/S - share repurchase programme https://www.biopharmawatch.com/news/ZJYL/jin-medical-supports-jiangsu-provincial-games BiopharmaWatch en 2026-11-03T14:20:00.000Z Jin Medical Supports the 12th Jiangsu Provincial Games for Persons with Disabilities with Professional Wheelchairs and Accessibility Services https://www.biopharmawatch.com/news/MMED/minimed-appoints-dr-david-segal-cmo BiopharmaWatch en 2026-11-03T14:20:00.000Z MiniMed Appoints Dr. David Segal as Chief Medical Officer https://www.biopharmawatch.com/news/PRE/prenetics-brian-rosin-cfo-transition BiopharmaWatch en 2026-11-03T14:06:41.000Z Prenetics’ IM8 Names Brian J. Rosin as Successor Chief Financial Officer https://www.biopharmawatch.com/news/GEHC/ge-healthcare-ai-lung-guidance-autoas-vscan-air BiopharmaWatch en 2026-11-03T14:00:00.000Z GE HealthCare reinforces leadership in AI with Lung Guidance and AutoAS on Vscan Air for point of care ultrasound assessments https://www.biopharmawatch.com/news/AMLX/amylyx-pharmaceuticals-november-investor-conferences BiopharmaWatch en 2026-11-03T14:00:00.000Z Amylyx Pharmaceuticals to Participate in Upcoming November Investor Conferences https://www.biopharmawatch.com/news/EVAX/evaxion-phase-2-trial-data-sitc-2026 BiopharmaWatch en 2026-11-03T14:00:00.000Z Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting https://www.biopharmawatch.com/news/BCTX/briacell-briaots-presentation-sitc-2026 BiopharmaWatch en 2026-11-03T14:00:00.000Z BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 https://www.biopharmawatch.com/news/BGLC/bglc-1lab-pilot-launch-gene-matrix BiopharmaWatch en 2026-11-03T14:00:00.000Z BioNexus Launches BGLC 1Lab Pilot for GeneMatrix Workflows at MRNA Scientific https://www.biopharmawatch.com/news/SBC/sbc-medical-announces-q3-2026-financial-results BiopharmaWatch en 2026-11-03T14:00:00.000Z SBC Medical to Announce 3Q 2026 Financial Results https://www.biopharmawatch.com/news/CAPR/capricor-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-03T14:00:00.000Z Capricor Therapeutics to Report Third Quarter 2026 Financial Results and Provide Recent Corporate Update on November 10 https://www.biopharmawatch.com/news/NEOG/neogen-participate-2026-ubs-global-healthcare-conference BiopharmaWatch en 2026-11-03T13:45:00.000Z Neogen® To Participate in 2026 UBS Global Healthcare Conference https://www.biopharmawatch.com/news/ONMD/onemednet-high-six-figure-order-multiyear-agreement BiopharmaWatch en 2026-11-03T13:40:00.000Z OneMedNet Receives High Six-Figure Add-On Order Under Multiyear Agreement Announced September 30 https://www.biopharmawatch.com/news/BEAT/heartbeam-third-quarter-2026-results-conference-call BiopharmaWatch en 2026-11-03T13:31:00.000Z HeartBeam to Host Third Quarter 2026 Results Conference Call on Thursday, November 12, 2026 at 4:30 p.m. Eastern Time https://www.biopharmawatch.com/news/LQDA/liquidia-corporation-q3-2026-results-webcast BiopharmaWatch en 2026-11-03T13:30:00.000Z Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/ALNY/alnylam-presents-helios-b-data-aha-isa-2026 BiopharmaWatch en 2026-11-03T13:30:00.000Z Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026 https://www.biopharmawatch.com/news/CELC/celcuity-participate-upcoming-investor-conferences-20261103 BiopharmaWatch en 2026-11-03T13:30:00.000Z Celcuity To Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ICU/fda-confirms-seastar-quellimmune-study-requirements BiopharmaWatch en 2026-11-03T13:21:00.000Z FDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric Patients https://www.biopharmawatch.com/news/RKTO/rocket-one-hoth-therapeutics-ht-001-phase-3 BiopharmaWatch en 2026-11-03T13:17:00.000Z Rocket One's Hoth Therapeutics Reports Strong HT-001 Efficacy Results, Ends Phase 2a Early and Plans to Pursue Phase 3 to Bring Treatment to Cancer Patients https://www.biopharmawatch.com/news/LUCD/lucid-diagnostics-esoguard-study-publication BiopharmaWatch en 2026-11-03T13:15:00.000Z Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study https://www.biopharmawatch.com/news/GH/guardant-health-prix-galien-award-shield-blood-test BiopharmaWatch en 2026-11-03T13:05:00.000Z Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test https://www.biopharmawatch.com/news/VIVS/vivosim-chemveda-ai-drug-testing BiopharmaWatch en 2026-11-03T13:05:00.000Z VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test https://www.biopharmawatch.com/news/ANRO/alto-neuroscience-announces-participation-upcoming-investor-conferences-20261103 BiopharmaWatch en 2026-11-03T13:03:00.000Z Alto Neuroscience Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ARDX/ardelyx-phase-3-accel-trial-ibsrela BiopharmaWatch en 2026-11-03T13:00:00.000Z Ardelyx Completes Enrollment in Phase 3 ACCEL Clinical Trial of IBSRELA® (tenapanor) in Adults with Chronic Idiopathic Constipation https://www.biopharmawatch.com/news/SRRK/scholar-rock-investor-conferences-november-2026 BiopharmaWatch en 2026-11-03T13:00:00.000Z Scholar Rock to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-investor-conferences-november BiopharmaWatch en 2026-11-03T13:00:00.000Z Stoke Therapeutics to Present at Upcoming Investor Conferences in November https://www.biopharmawatch.com/news/NTLA/intellia-nexiguran-ziclumeran-presentations BiopharmaWatch en 2026-11-03T13:00:00.000Z Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress Presentations https://www.biopharmawatch.com/news/CALC/calcimedica-guggenheim-healthcare-innovation-conference BiopharmaWatch en 2026-11-03T13:00:00.000Z CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/SEPN/septerna-participate-upcoming-investor-conferences-20261103 BiopharmaWatch en 2026-11-03T13:00:00.000Z Septerna to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/URGN/urogen-pharma-guggenheim-conference-2026 BiopharmaWatch en 2026-11-03T13:00:00.000Z UroGen Pharma to Present at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/NAMS/newamsterdam-pharma-investor-conferences-november-2026 BiopharmaWatch en 2026-11-03T13:00:00.000Z NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November https://www.biopharmawatch.com/news/ERAS/erasca-present-upcoming-conferences-november-2026 BiopharmaWatch en 2026-11-03T13:00:00.000Z Erasca to Present at Upcoming Conferences in November https://www.biopharmawatch.com/news/CTY/city-therapeutics-november-investor-conferences BiopharmaWatch en 2026-11-03T13:00:00.000Z City Therapeutics to Present at Upcoming November Investor Conferences https://www.biopharmawatch.com/news/GERN/geron-participate-stifel-2026-healthcare-conference BiopharmaWatch en 2026-11-03T13:00:00.000Z Geron Corporation to Participate in the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/HUMA/humacyte-research-coronary-bypass-vascular-regeneration BiopharmaWatch en 2026-11-03T13:00:00.000Z Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/CABA/cabaletta-bio-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-03T13:00:00.000Z Cabaletta Bio to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AVLN/avalyn-present-upcoming-investor-conferences BiopharmaWatch en 2026-11-03T13:00:00.000Z Avalyn to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/BOLT/bolt-biotherapeutics-participate-upcoming-conferences BiopharmaWatch en 2026-11-03T13:00:00.000Z Bolt Biotherapeutics to Participate in Upcoming Conferences https://www.biopharmawatch.com/news/FDMT/4dmt-participate-investor-conferences-nov-dec-2026 BiopharmaWatch en 2026-11-03T13:00:00.000Z 4DMT to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/LNSR/lensar-third-quarter-2026-results-release BiopharmaWatch en 2026-11-03T13:00:00.000Z LENSAR® to Report Third Quarter 2026 Results on November 10th, 2026 https://www.biopharmawatch.com/news/ALLO/allogene-sitc-annual-meeting-2026 BiopharmaWatch en 2026-11-03T13:00:00.000Z Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting https://www.biopharmawatch.com/news/PHAT/phathom-voquezna-zero-cost-offer-blinkrx BiopharmaWatch en 2026-11-03T13:00:00.000Z Phathom Pharmaceuticals Announces Eligible Commercially Insured Patients May Now Pay as Little as $0 for VOQUEZNA® (vonoprazan) Tablets Exclusively at BlinkRx https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-q3-2026-results-announcement BiopharmaWatch en 2026-11-03T13:00:00.000Z Milestone Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 13, 2026 https://www.biopharmawatch.com/news/ELAN/elanco-participate-ubs-global-healthcare-conference BiopharmaWatch en 2026-11-03T12:53:00.000Z Elanco to Participate in UBS Global Healthcare Conference https://www.biopharmawatch.com/news/DCGO/docgo-third-quarter-2026-results-announcement BiopharmaWatch en 2026-11-03T12:35:00.000Z DocGo to Announce Third Quarter 2026 Results on Monday, November 9, 2026 https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-participate-two-upcoming-investor-conferences-london BiopharmaWatch en 2026-11-03T12:30:35.000Z Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London https://www.biopharmawatch.com/news/AAPG/ascentage-pharma-investor-conferences-london BiopharmaWatch en 2026-11-03T12:30:35.000Z Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London https://www.biopharmawatch.com/news/INM/inmed-reports-fiscal-2027-results-and-corporate-update BiopharmaWatch en 2026-11-03T12:30:00.000Z InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/FTH/faeth-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-03T12:30:00.000Z Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates https://www.biopharmawatch.com/news/NGNE/neurogene-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-03T12:30:00.000Z Neurogene to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BBNX/beta-bionics-participation-investor-conferences BiopharmaWatch en 2026-11-03T12:30:00.000Z Beta Bionics Announces Participation at Upcoming Investor Conferences https://www.biopharmawatch.com/news/PVLA/palvella-therapeutics-stifel-2026-healthcare-conference BiopharmaWatch en 2026-11-03T12:30:00.000Z Palvella Therapeutics to Participate in the Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/LAB/archimed-acquires-standard-biotech-microfluidics-business BiopharmaWatch en 2026-11-03T12:30:00.000Z ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific https://www.biopharmawatch.com/news/HELP/helus-pharma-guggenheim-healthcare-conference BiopharmaWatch en 2026-11-03T12:30:00.000Z Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference https://www.biopharmawatch.com/news/BBIO/bridgebio-acoramidis-data-heart-failure-aha-2026 BiopharmaWatch en 2026-11-03T12:30:00.000Z BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026 https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-present-november-investor-conferences BiopharmaWatch en 2026-11-03T12:15:00.000Z ADC Therapeutics to Present at November Investor Conferences https://www.biopharmawatch.com/news/KLRA/kailera-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-11-03T12:15:00.000Z Kailera Therapeutics to Participate in November Investor Conferences https://www.biopharmawatch.com/news/DCOY/decoy-therapeutics-q3-2026-update BiopharmaWatch en 2026-11-03T12:15:00.000Z Decoy Therapeutics Provides Third Quarter 2026 Business Update https://www.biopharmawatch.com/news/USNA/usana-biomega-consumerlab-seal-approval BiopharmaWatch en 2026-11-03T12:06:00.000Z USANA BiOmega Earns ConsumerLab Seal of Approval for Quality and Purity https://www.biopharmawatch.com/news/ALKS/alkermes-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-03T12:05:00.000Z Alkermes plc Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/CDNA/caredx-third-koar-analysis-transplantation BiopharmaWatch en 2026-11-03T12:05:00.000Z CareDx Announces Third KOAR Analysis Published in Transplantation https://www.biopharmawatch.com/news/RGNX/regenxbio-participate-stifel-2026-healthcare-conference BiopharmaWatch en 2026-11-03T12:05:00.000Z REGENXBIO to Participate in Stifel 2026 Healthcare Conference https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-03T12:01:00.000Z Definium Therapeutics to Participate at Upcoming Investor Conferences https://www.biopharmawatch.com/news/DTIL/precision-biosciences-reports-third-quarter-2026-financial-results-provides-business BiopharmaWatch en 2026-11-03T12:01:00.000Z Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/IVVD/invivyd-reports-inducement-grants-nasdaq-listing-rule-5635-c-4-20261103 BiopharmaWatch en 2026-11-03T12:01:00.000Z Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-guggenheim-conference-2026 BiopharmaWatch en 2026-11-03T12:00:56.000Z BlossomHill Therapeutics to Present at Guggenheim’s 3rd Annual Healthcare Innovations Conference https://www.biopharmawatch.com/news/TNGX/tango-therapeutics-guggenheim-healthcare-conference BiopharmaWatch en 2026-11-03T12:00:52.000Z Tango Therapeutics to Participate in Guggenheim’s 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/RAPP/rapport-therapeutics-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-03T12:00:52.000Z Rapport Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BEAM/beam-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-03T12:00:37.000Z Beam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio https://www.biopharmawatch.com/news/KTTA/pasithea-fda-clearance-ind-pas-004-nf1-cnf BiopharmaWatch en 2026-11-03T12:00:21.000Z Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF) https://www.biopharmawatch.com/news/ULS/ul-solutions-third-quarter-2026-results BiopharmaWatch en 2026-11-03T12:00:00.000Z UL Solutions Inc. Reports Strong Third Quarter 2026 Results https://www.biopharmawatch.com/news/SRTA/strata-critical-medical-q3-2026-results BiopharmaWatch en 2026-11-03T12:00:00.000Z Strata Critical Medical Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/IFRX/inflarx-izicopan-development-anva-associated-vasculitis BiopharmaWatch en 2026-11-03T12:00:00.000Z InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day https://www.biopharmawatch.com/news/TEVA/teva-growth-strategy-2026-outlook BiopharmaWatch en 2026-11-03T12:00:00.000Z Teva’s Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO®, AJOVY® and UZEDY®; Delivers Substantial Gross Margin Expansion https://www.biopharmawatch.com/news/NTRA/medicare-expands-signatera-mrd-test-coverage-hcc BiopharmaWatch en 2026-11-03T12:00:00.000Z Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma https://www.biopharmawatch.com/news/PODD/insulet-2026-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-03T12:00:00.000Z Insulet to Participate in the 2026 Jefferies Global Healthcare Conference in London https://www.biopharmawatch.com/news/GKOS/glaukos-announces-participation-upcoming-investor-conferences BiopharmaWatch en 2026-11-03T12:00:00.000Z Glaukos Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AHCO/adapthealth-q3-2026-results BiopharmaWatch en 2026-11-03T12:00:00.000Z AdaptHealth Corp. Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/CGEN/compugen-participate-november-investor-conferences BiopharmaWatch en 2026-11-03T12:00:00.000Z Compugen to Participate in November Investor Conferences https://www.biopharmawatch.com/news/PTCT/ptc-therapeutics-share-repurchase-program BiopharmaWatch en 2026-11-03T12:00:00.000Z PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program https://www.biopharmawatch.com/news/FMS/fresenius-medical-care-q3-2026-performance BiopharmaWatch en 2026-11-03T12:00:00.000Z Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook https://www.biopharmawatch.com/news/MCRB/seres-therapeutics-ser-155-phase-1b-results BiopharmaWatch en 2026-11-03T12:00:00.000Z Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients https://www.biopharmawatch.com/news/JBIO/jade-biosciences-upcoming-conferences BiopharmaWatch en 2026-11-03T12:00:00.000Z Jade Biosciences to Participate in Upcoming Conferences https://www.biopharmawatch.com/news/AXSM/axsome-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-11-03T12:00:00.000Z Axsome Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/COAG/hemab-therapeutics-third-quarter-2026-update BiopharmaWatch en 2026-11-03T12:00:00.000Z Hemab Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 10, 2026 https://www.biopharmawatch.com/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-grant BiopharmaWatch en 2026-11-03T12:00:00.000Z Cartesian Therapeutics Announces New Employment Inducement Grant https://www.biopharmawatch.com/news/PBLS/parabilis-medicines-november-investor-conferences BiopharmaWatch en 2026-11-03T12:00:00.000Z Parabilis Medicines to Participate in Upcoming November Investor Conferences https://www.biopharmawatch.com/news/FHTX/foghorn-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-11-03T12:00:00.000Z Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November https://www.biopharmawatch.com/news/SHC/sotera-health-q3-2026-results BiopharmaWatch en 2026-11-03T12:00:00.000Z Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results https://www.biopharmawatch.com/news/ORKA/oruka-therapeutics-upcoming-conferences BiopharmaWatch en 2026-11-03T12:00:00.000Z Oruka Therapeutics to Participate in Multiple Upcoming Conferences https://www.biopharmawatch.com/news/ARVN/arvinas-reports-q3-2026-results-update BiopharmaWatch en 2026-11-03T12:00:00.000Z Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-q3-2026-results-update BiopharmaWatch en 2026-11-03T12:00:00.000Z Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-november-investor-conferences BiopharmaWatch en 2026-11-03T12:00:00.000Z C4 Therapeutics to Participate in Upcoming November Investor Conferences https://www.biopharmawatch.com/news/MDGL/madrigal-pharmaceuticals-q3-2026-results-updates BiopharmaWatch en 2026-11-03T12:00:00.000Z Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates https://www.biopharmawatch.com/news/RLMD/relmada-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-03T12:00:00.000Z Relmada Therapeutics to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026 https://www.biopharmawatch.com/news/AXGN/axogen-inc-participate-multiple-upcoming-investor-conferences BiopharmaWatch en 2026-11-03T12:00:00.000Z Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences https://www.biopharmawatch.com/news/CRDF/cardiff-oncology-ubs-global-biopharma-conference BiopharmaWatch en 2026-11-03T12:00:00.000Z Cardiff Oncology to Participate in the UBS Global Biopharma Conference https://www.biopharmawatch.com/news/AVXL/anavex-life-sciences-appoints-terrie-kellmeyer-ceo BiopharmaWatch en 2026-11-03T12:00:00.000Z Anavex Life Sciences Names Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer and Member of the Board of Directors https://www.biopharmawatch.com/news/MAZE/maze-therapeutics-participate-upcoming-investor-conferences BiopharmaWatch en 2026-11-03T12:00:00.000Z Maze Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PMN/promis-neurosciences-q3-2026-results-update BiopharmaWatch en 2026-11-03T12:00:00.000Z ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026 https://www.biopharmawatch.com/news/IRD/opus-genetics-guggenheim-healthcare-conference-2026 BiopharmaWatch en 2026-11-03T12:00:00.000Z Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/KURA/kura-oncology-third-quarter-results-november-2026 BiopharmaWatch en 2026-11-03T11:58:00.000Z Kura Oncology to Report Third Quarter Financial Results on November 10 https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-upcoming-investor-conferences BiopharmaWatch en 2026-11-03T11:55:00.000Z ANI Pharmaceuticals to Present at Upcoming November Investor Conferences https://www.biopharmawatch.com/news/PLX/protalix-announces-q3-2026-results-update BiopharmaWatch en 2026-11-03T11:50:00.000Z Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026 https://www.biopharmawatch.com/news/PFE/pfizer-reports-strong-q3-2026-results BiopharmaWatch en 2026-11-03T11:45:00.000Z Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance https://www.biopharmawatch.com/news/MRK/merck-phase-3-study-ohtuvayre-copd BiopharmaWatch en 2026-11-03T11:45:00.000Z Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations https://www.biopharmawatch.com/news/BNTX/biontech-announces-third-quarter-2026-financial-results-corporate-update BiopharmaWatch en 2026-11-03T11:45:00.000Z BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update https://www.biopharmawatch.com/news/PFE/pfizer-appoints-cecile-guegan-cfo BiopharmaWatch en 2026-11-03T11:40:00.000Z Pfizer Appoints Cecile Guegan as Chief Financial Officer https://www.biopharmawatch.com/news/INFU/infusystem-change-q3-2026-earnings-release-date BiopharmaWatch en 2026-11-03T11:30:00.000Z InfuSystem Announces Change in Third Quarter 2026 Earnings Release Date https://www.biopharmawatch.com/news/STVN/stevanato-group-q3-2026-revenue-growth BiopharmaWatch en 2026-11-03T11:30:00.000Z Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026 https://www.biopharmawatch.com/news/CMPS/compass-pathways-q3-2026-results BiopharmaWatch en 2026-11-03T11:30:00.000Z Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights https://www.biopharmawatch.com/news/ONC/beone-medicines-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-03T11:01:00.000Z BeOne Medicines to Present at the Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/RMTI/vantive-divests-hemodialysis-assets-rockwell-medical BiopharmaWatch en 2026-11-03T11:01:00.000Z Vantive Announces Agreement to Divest Majority of Hemodialysis Assets and Associated Operations to Rockwell Medical https://www.biopharmawatch.com/news/RMTI/rockwell-medical-global-hemodialysis-acquisition BiopharmaWatch en 2026-11-03T11:00:00.000Z Rockwell Medical Announces Transformational Global Hemodialysis Acquisition https://www.biopharmawatch.com/news/HSIC/henry-schein-reports-strong-q3-2026-results BiopharmaWatch en 2026-11-03T11:00:00.000Z Henry Schein Reports Strong 2026 Third Quarter and Raises FY2026 Guidance https://www.biopharmawatch.com/news/RVTY/revvity-financial-results-q3-2026 BiopharmaWatch en 2026-11-03T11:00:00.000Z Revvity Announces Financial Results for the Third Quarter of 2026 https://www.biopharmawatch.com/news/IDYA/ideaya-biosciences-q3-2026-financial-results-update BiopharmaWatch en 2026-11-03T11:00:00.000Z IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update https://www.biopharmawatch.com/news/WAT/waters-corporation-q3-2026-financial-results BiopharmaWatch en 2026-11-03T11:00:00.000Z Waters Corporation (NYSE: WAT) Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/AMRX/amneal-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-03T11:00:00.000Z Amneal Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/WAT/waters-acquires-mobilion-systems-ion-mobility-separation BiopharmaWatch en 2026-11-03T10:55:00.000Z Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation to its Mass Spectrometry Portfolio with the Speed and Resolution AI Workflows Require for Proteomics Biomarker Discovery https://www.biopharmawatch.com/news/TEVA/teva-samsung-bioepis-biosimilars-agreement BiopharmaWatch en 2026-11-03T10:00:00.000Z Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S. https://www.biopharmawatch.com/news/PLUR/pluri-zeo-scientifix-partner-manufacturing-expansion BiopharmaWatch en 2026-11-03T09:41:59.000Z Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform https://www.biopharmawatch.com/news/VCRE/vicore-nomination-committee-2027-agm BiopharmaWatch en 2026-11-03T07:20:00.000Z Vicore Announces the Nomination Committee for the 2027 Annual General Meeting https://www.biopharmawatch.com/news/PHG/philips-q3-2026-results-order-intake-sales-growth BiopharmaWatch en 2026-11-03T06:00:00.000Z Philips delivers strong order intake growth, comparable sales growth and strong margin expansion in Q3; 2026 outlook reiterated https://www.biopharmawatch.com/news/ARGX/argenx-upcoming-investor-conferences-november-2026 BiopharmaWatch en 2026-11-03T06:00:00.000Z argenx to Present at Upcoming Investor Conferences https://www.biopharmawatch.com/news/IBO/impact-biomedical-zoar-sec-f4-registration BiopharmaWatch en 2026-11-03T04:25:00.000Z Impact Biomedical Inc. and Zoar Limited Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement, Marking Major Milestone Toward Closing of Proposed Business Combination https://www.biopharmawatch.com/news/RYTM/rhythm-pharmaceuticals-lg-chem-amendment-license-agreement BiopharmaWatch en 2026-11-03T02:59:00.000Z Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement https://www.biopharmawatch.com/news/ILMN/illumina-precision-medicine-singapore BiopharmaWatch en 2026-11-03T01:00:00.000Z Illumina selected to help bring precision medicine into everyday healthcare in Singapore https://www.biopharmawatch.com/news/ALMR/alamar-biosciences-nightingale-health-uk-biobank-study BiopharmaWatch en 2026-11-03T00:05:00.000Z UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease Study https://www.biopharmawatch.com/news/AGEN/agenus-participate-rodman-renshaw-fireside-chat BiopharmaWatch en 2026-11-02T23:05:00.000Z Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261102 BiopharmaWatch en 2026-11-02T22:00:00.000Z Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/ZNTL/zentalis-pharmaceuticals-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261102 BiopharmaWatch en 2026-11-02T22:00:00.000Z Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-q3-2026-results-call BiopharmaWatch en 2026-11-02T22:00:00.000Z Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026 https://www.biopharmawatch.com/news/NBIX/neurocrine-biosciences-q3-2026-results BiopharmaWatch en 2026-11-02T21:49:00.000Z Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results https://www.biopharmawatch.com/news/TLX/cancellation-of-appendix-2a-telix-pharmaceuticals BiopharmaWatch en 2026-11-02T21:40:51.000Z Cancellation of Appendix 2A https://www.biopharmawatch.com/news/IRD/opus-genetics-reports-inducement-grants-nasdaq-listing-rule-5635-c-20261102 BiopharmaWatch en 2026-11-02T21:39:00.000Z Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/INKT/mink-therapeutics-q3-2026-results-inkt-therapy-update BiopharmaWatch en 2026-11-02T21:35:00.000Z MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy https://www.biopharmawatch.com/news/MSA/msa-safety-third-quarter-2026-results BiopharmaWatch en 2026-11-02T21:30:00.000Z MSA Safety Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/IBIO/ibio-participate-investor-conferences-nov-dec-2026 BiopharmaWatch en 2026-11-02T21:30:00.000Z iBio to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-acquires-vans-institutional-pharmacy BiopharmaWatch en 2026-11-02T21:30:00.000Z Guardian Pharmacy Services Acquires Van’s Institutional Pharmacy, Expanding Footprint in Tennessee and Kentucky https://www.biopharmawatch.com/news/ACHC/acadia-healthcare-november-investor-conferences BiopharmaWatch en 2026-11-02T21:30:00.000Z Acadia Healthcare to Participate in November Investor Conferences https://www.biopharmawatch.com/news/HSTM/healthstream-announces-third-quarter-2026-results BiopharmaWatch en 2026-11-02T21:30:00.000Z HealthStream Announces Third Quarter 2026 Results https://www.biopharmawatch.com/news/GRDN/guardian-pharmacy-services-stephens-investment-conference BiopharmaWatch en 2026-11-02T21:30:00.000Z Guardian Pharmacy Services, Inc. to Participate in Upcoming Stephens Investment Conference https://www.biopharmawatch.com/news/DHR/danaher-presents-ubs-jefferies-healthcare-conferences BiopharmaWatch en 2026-11-02T21:30:00.000Z Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences https://www.biopharmawatch.com/news/OLMA/olema-oncology-participate-upcoming-investor-conferences-20261102 BiopharmaWatch en 2026-11-02T21:30:00.000Z Olema Oncology to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/DBVT/dbv-technologies-november-investor-conferences BiopharmaWatch en 2026-11-02T21:30:00.000Z DBV Technologies to Participate in Upcoming November Investor Conferences https://www.biopharmawatch.com/news/RXRX/recursion-reports-q3-2026-results-and-clinical-data BiopharmaWatch en 2026-11-02T21:30:00.000Z Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair https://www.biopharmawatch.com/news/INSP/inspire-medical-systems-q3-2026-results BiopharmaWatch en 2026-11-02T21:28:00.000Z Inspire Medical Systems, Inc. Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/IONS/ionis-third-quarter-2026-financial-results-webcast BiopharmaWatch en 2026-11-02T21:27:00.000Z Ionis to hold third quarter 2026 financial results webcast https://www.biopharmawatch.com/news/RXRX/new-phase-2-rec-4881-data-fap-polyp-burden-reduction BiopharmaWatch en 2026-11-02T21:25:00.000Z New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps https://www.biopharmawatch.com/news/RXRX/recursion-phase-2-rec-4881-data-cga-igc BiopharmaWatch en 2026-11-02T21:25:00.000Z New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps https://www.biopharmawatch.com/news/INM/inmed-share-consolidation-merger-mentari BiopharmaWatch en 2026-11-02T21:15:00.000Z InMed Announces Share Consolidation in Connection with Proposed Merger https://www.biopharmawatch.com/news/INO/inovio-q3-2026-financial-results-release BiopharmaWatch en 2026-11-02T21:15:00.000Z INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026 https://www.biopharmawatch.com/news/ELOX/eloxx-pharmaceuticals-guggenheim-conference-2026 BiopharmaWatch en 2026-11-02T21:15:00.000Z Eloxx Pharmaceuticals to Present at the 3rd Annual Guggenheim Healthcare Innovation Conference https://www.biopharmawatch.com/news/ISRG/intuitive-appoints-aaron-martin-board-directors BiopharmaWatch en 2026-11-02T21:15:00.000Z Intuitive Appoints Aaron Martin to its Board of Directors https://www.biopharmawatch.com/news/MDLN/medline-participation-jefferies-global-healthcare-conference BiopharmaWatch en 2026-11-02T21:15:00.000Z Medline announces participation in the 2026 Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/HLF/herbalife-q3-2026-sales-growth BiopharmaWatch en 2026-11-02T21:10:00.000Z Herbalife Achieves Third Quarter Net Sales Growth of 6.0%; Strong Profitability and Robust Operating Cash Flow; Fifth Consecutive Quarter of Expansion https://www.biopharmawatch.com/news/SIBN/si-bone-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-02T21:09:00.000Z SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance https://www.biopharmawatch.com/news/KRSA/korsana-biosciences-investor-conferences-2026 BiopharmaWatch en 2026-11-02T21:05:47.000Z Korsana Biosciences to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AIRS/airsculpt-announces-earnings-release-date-q3-2026 BiopharmaWatch en 2026-11-02T21:05:33.000Z AirSculpt Technologies Announces Earnings Release Date, Conference Call, and Webcast for Third Quarter Fiscal 2026 Results https://www.biopharmawatch.com/news/TCMD/tactile-systems-technology-q3-2026-results BiopharmaWatch en 2026-11-02T21:05:00.000Z Tactile Systems Technology, Inc. Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RXRX/recursion-appoints-fred-hassan-chair-board BiopharmaWatch en 2026-11-02T21:05:00.000Z Recursion Appoints Fred Hassan as Chair of the Board https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-q3-2026-financial-results BiopharmaWatch en 2026-11-02T21:05:00.000Z Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/JAZZ/jazz-pharmaceuticals-q3-2026-results BiopharmaWatch en 2026-11-02T21:05:00.000Z Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/MYO/myomo-q3-2026-financial-results-report BiopharmaWatch en 2026-11-02T21:05:00.000Z Myomo to Report Third Quarter 2026 Financial Results on November 9 https://www.biopharmawatch.com/news/ACOG/alpha-cognition-third-quarter-2026-results BiopharmaWatch en 2026-11-02T21:05:00.000Z Alpha Cognition to Report Third Quarter 2026 Financial Results and Provide Business Update https://www.biopharmawatch.com/news/CERS/cerus-corporation-q3-2026-financial-results BiopharmaWatch en 2026-11-02T21:05:00.000Z Cerus Corporation Announces Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/RCUS/arcus-biosciences-jefferies-global-healthcare-conference-2026 BiopharmaWatch en 2026-11-02T21:05:00.000Z Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London https://www.biopharmawatch.com/news/SPRB/spruce-biosciences-guggenheim-healthcare-conference BiopharmaWatch en 2026-11-02T21:05:00.000Z Spruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference https://www.biopharmawatch.com/news/CNMD/conmed-participate-jefferies-healthcare-conference-2026 BiopharmaWatch en 2026-11-02T21:05:00.000Z CONMED Corporation to Participate in the Jefferies Global Healthcare Conference https://www.biopharmawatch.com/news/VIR/vir-biotechnology-jefferies-2026-london-conference BiopharmaWatch en 2026-11-02T21:05:00.000Z Vir Biotechnology to Participate in the Jefferies 2026 London Healthcare Conference https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-reports-q3-2026-results BiopharmaWatch en 2026-11-02T21:05:00.000Z Emergent Biosolutions Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/HNGE/hinge-health-q3-2026-financial-results BiopharmaWatch en 2026-11-02T21:05:00.000Z Hinge Health reports record third quarter 2026 financial results https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-announces-new-employee-inducement-grant-20261102 BiopharmaWatch en 2026-11-02T21:05:00.000Z ADC Therapeutics Announces New Employee Inducement Grant https://www.biopharmawatch.com/news/REGN/regeneron-announces-investor-conference-presentations BiopharmaWatch en 2026-11-02T21:05:00.000Z Regeneron Announces Investor Conference Presentations https://www.biopharmawatch.com/news/TRVI/trevi-therapeutics-q3-2026-results-update BiopharmaWatch en 2026-11-02T21:05:00.000Z Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026 https://www.biopharmawatch.com/news/KIDS/orthopediatrics-participate-upcoming-conferences-20261102 BiopharmaWatch en 2026-11-02T21:05:00.000Z OrthoPediatrics to Participate in Upcoming Conferences https://www.biopharmawatch.com/news/SPRO/spero-therapeutics-investor-conferences-november BiopharmaWatch en 2026-11-02T21:05:00.000Z Spero Therapeutics to Present at Investor Conferences in November https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-q3-2026-conference-call BiopharmaWatch en 2026-11-02T21:05:00.000Z Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026 https://www.biopharmawatch.com/news/RLAY/relay-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-11-02T21:05:00.000Z Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November https://www.biopharmawatch.com/news/BVS/bioventus-reports-q3-financial-results-2026 BiopharmaWatch en 2026-11-02T21:05:00.000Z Bioventus Reports Third Quarter Financial Results https://www.biopharmawatch.com/news/CADL/candel-therapeutics-announces-inducement-grants-nasdaq-listing-rule-5635-c-20261102 BiopharmaWatch en 2026-11-02T21:05:00.000Z Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/MYGN/myriad-genetics-upcoming-investor-healthcare-conferences BiopharmaWatch en 2026-11-02T21:05:00.000Z Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences https://www.biopharmawatch.com/news/ABVX/abivax-participate-fall-investor-conferences BiopharmaWatch en 2026-11-02T21:05:00.000Z Abivax to Participate in Upcoming Fall Investor Conferences https://www.biopharmawatch.com/news/BMRN/biomarin-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-02T21:03:00.000Z BioMarin Reports Third Quarter 2026 Financial and Operating Results https://www.biopharmawatch.com/news/CVRX/cvrx-participate-investor-conferences BiopharmaWatch en 2026-11-02T21:02:08.000Z CVRx to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/JANX/janux-therapeutics-phase-1-data-presentation BiopharmaWatch en 2026-11-02T21:02:00.000Z Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers https://www.biopharmawatch.com/news/TVTX/travere-therapeutics-q3-2026-results BiopharmaWatch en 2026-11-02T21:01:00.000Z Travere Therapeutics Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/VRTX/vertex-reports-q3-2026-financial-results BiopharmaWatch en 2026-11-02T21:01:00.000Z Vertex Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/INO/inovio-participate-upcoming-scientific-conferences BiopharmaWatch en 2026-11-02T21:01:00.000Z INOVIO to Participate in Upcoming Scientific Conferences https://www.biopharmawatch.com/news/XENE/xenon-report-q3-2026-financial-results BiopharmaWatch en 2026-11-02T21:01:00.000Z Xenon to Report Q3 2026 Financial Results on November 9, 2026 https://www.biopharmawatch.com/news/DNTH/dianthus-therapeutics-investor-conferences-november-2026 BiopharmaWatch en 2026-11-02T21:01:00.000Z Dianthus Therapeutics to Participate in Five Investor Conferences During November https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-q3-2026-financial-results BiopharmaWatch en 2026-11-02T21:01:00.000Z CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results https://www.biopharmawatch.com/news/SNDX/syndax-reports-q3-2026-results-business-update BiopharmaWatch en 2026-11-02T21:01:00.000Z Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-inducement-grant-nasdaq-rule-5635c4 BiopharmaWatch en 2026-11-02T21:01:00.000Z C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/SNDX/syndax-announces-cfo-transition-aaron-ondrey BiopharmaWatch en 2026-11-02T21:01:00.000Z Syndax Announces CFO Transition – Aaron A. Ondrey Appointed Chief Financial Officer https://www.biopharmawatch.com/news/LKFT/lakefront-biotherapeutics-dr-mehdi-shahidi-board-appointment BiopharmaWatch en 2026-11-02T21:01:00.000Z Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors https://www.biopharmawatch.com/news/CERS/cerus-positive-topline-results-redes-trial BiopharmaWatch en 2026-11-02T21:00:00.000Z Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells https://www.biopharmawatch.com/news/ALGN/align-technology-2027-research-award-program BiopharmaWatch en 2026-11-02T21:00:00.000Z Align Technology Opens 2027 Annual Research Program to Advance Orthodontic and Dental Patient Care https://www.biopharmawatch.com/news/ASMB/assembly-biosciences-investor-conferences-november-2026 BiopharmaWatch en 2026-11-02T21:00:00.000Z Assembly Biosciences to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AVTX/avalo-therapeutics-investor-conferences BiopharmaWatch en 2026-11-02T21:00:00.000Z Avalo Therapeutics to Participate in Upcoming Investor Conferences